Cargando…

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Detalles Bibliográficos
Autores principales:	Gombos, Andrea, Venet, David, Ameye, Lieveke, Vuylsteke, Peter, Neven, Patrick, Richard, Vincent, Duhoux, Francois P., Laes, Jean-Francois, Rothe, Françoise, Sotiriou, Christos, Paesmans, Marianne, Awada, Ahmad, Guiot, Thomas, Flamen, Patrick, Piccart-Gebhart, Martine, Ignatiadis, Michail, Gebhart, Géraldine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927125/ https://www.ncbi.nlm.nih.gov/pubmed/35296682 http://dx.doi.org/10.1038/s41523-022-00409-x

Ejemplares similares

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2016)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
por: Vandeputte, Caroline, et al.
Publicado: (2018)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
por: de Azambuja, E, et al.
Publicado: (2007)

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials
por: Charette, Nicolas, et al.
Publicado: (2019)

New generation of breast cancer clinical trials implementing molecular profiling
por: Zardavas, Dimitrios, et al.
Publicado: (2016)

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by (89)Zr-Trastuzumab and (18)F-FDG PET imaging
por: Wimana, Zéna, et al.
Publicado: (2017)

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
por: Buisseret, Laurence, et al.
Publicado: (2023)

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
por: Rossari, José R., et al.
Publicado: (2012)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer
por: Hendlisz, Alain, et al.
Publicado: (2015)

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial
por: De Caluwé, Alex, et al.
Publicado: (2021)

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
por: El Hachem, Georges, et al.
Publicado: (2019)

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
por: Hendlisz, Alain, et al.
Publicado: (2015)

Are Intensive Cares Worthwhile for Breast Cancer Patients: The Experience of an Oncological ICU
por: Destrebecq, Virginie, et al.
Publicado: (2016)

The current use and attitudes towards tumor genome sequencing in breast cancer
por: Gingras, I., et al.
Publicado: (2016)

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
por: Sonnenblick, Amir, et al.
Publicado: (2015)

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
por: Sonnenblick, Amir, et al.
Publicado: (2015)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer
por: Woff, Erwin, et al.
Publicado: (2016)

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study
por: Deleporte, Amelie, et al.
Publicado: (2014)

pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation
por: Sonnenblick, Amir, et al.
Publicado: (2019)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

How I treat endocrine-dependent metastatic breast cancer
por: Gombos, A., et al.
Publicado: (2023)

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients
por: Lambertini, Matteo, et al.
Publicado: (2016)

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis
por: Rothé, Françoise, et al.
Publicado: (2022)

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis
por: Martins-Branco, Diogo, et al.
Publicado: (2022)

Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report
por: Mhamdi, Hasnae Alaoui, et al.
Publicado: (2017)

Everolimus in acute kidney injury in a patient with breast cancer: a case report
por: Donders, Francesca, et al.
Publicado: (2014)

Heat conduction and mass diffusion
por: Gebhart, Benjamin
Publicado: (1993)

Heat conduction and mass diffusion
por: Gebhart, Benjamin
Publicado: (1993)

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
por: Rothé, Françoise, et al.
Publicado: (2011)

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
por: Hendlisz, Alain, et al.
Publicado: (2013)

Two Years’ Experience with a Dental Program
por: Gebhart, John C.
Publicado: (1922)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations
por: Nguyen, Bastien, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qo4jm75otv4p44tv5nq1fng9bh